EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Rodrigo Jiménez-Saiz iD, Salvador Iborra iD, Carlos Blanco iD, Ruperto González-Pérez iD, Emilio Nuñez-Borque iD, Can Zeyneloglu iD, Huseyn Babayev iD, Ozlem Göksel iD, Tuncay Göksel iD, Musa Khaitov iD, Dmitry Kudlay iD, Yadong Gao iD and 11 more

Allergy · 2026-11 · 81 (11) · 3825-3852

DOI: 10.1111/all.70512 ↗

At a glance

Übersichtsarbeit in Allergy, published online on 2026-09-09. Written by Rodrigo Jiménez-Saiz and 22 co-authors. Institution: Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain. Major MEDLINE topics: Hypersensitivity, Th2 Cells, Immunity. Cited 3 times so far (Crossref); 297 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (MICIU), Fundación Domingo Martínez.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue protection and repair. There are major clues from the early evolution of T2 responses for protection against massive tissue damage and positive selection for survival against parasites starting over 500 million years ago. These responses likely co‐evolved stepwise with immune‐regulatory circuits, culminating in the emergence of the fully functional human‐type IgG4 in the great apes (Hominidae) within the last ~10 million years. The involvement of body barriers along with the strong influence of local epithelial cells and their interaction with the microbiome and the immune system is a common characteristic of T2 inflammation. An expanding list of new T2 diseases is being reported, characterized by epithelial cell and immune system activation, epithelial barrier damage, and microbial dysbiosis, including opportunistic pathogen colonization and loss of commensals. This evolving understanding coincides with the clinical success of biologics targeting key T2 mediators such as IL‐4, IL‐5, IL‐13, IL‐31, TSLP, and IgE, which have transformed the management of severe allergic diseases and other T2‐driven pathologies. However, the contribution of T2 immunity to homeostatic programs raises questions about the long‐term consequences of sustained T2 suppression. In this review, we examine the dual role of T2 immunity in health and disease, revisit its evolutionary origins, highlight its protective functions beyond allergy, and discuss the potential implications of prolonged T2 pathway blockade.

Subjects

MeSH terms (MEDLINE)

HypersensitivityTh2 CellsImmunityHumansAnimalsDisease SusceptibilityCytokines

Author keywords

Type 2 immunityallergybiologicshomeostasisinflammation

Substances

Cytokines

Authors and institutions

  • Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.
  • Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.
  • Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Canada.
  • Fundación Inmunotek, Alcalá de Henares, Spain.
  • Department of Allergy, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.
  • Department of Allergy, Hospital Universitario de Canarias (HUC), Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.

ORCID profiles: Rodrigo Jiménez-Saiz, Salvador Iborra, Carlos Blanco, Ruperto González-Pérez, Emilio Nuñez-Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie-Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J Torres, Mohamed Shamji, Mübeccel Akdis, Kari C Nadeau, Ismail Ogulur, Cezmi A Akdis

Funding

  • Instituto de Salud Carlos III (ISCIII)
  • Ministerio de Ciencia, Innovación y Universidades (MICIU)
  • Fundación Domingo Martínez
  • Weston Family Foundation
  • Comunidad de Madrid
  • IIS-Princesa
  • Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
  • BBVA Foundation

Cite

APA

Jiménez-Saiz, R., Iborra, S., Blanco, C., González-Pérez, R., Nuñez-Borque, E., Zeyneloglu, C., Babayev, H., Göksel, O., Göksel, T., Khaitov, M., Kudlay, D., Gao, Y., Sevim, M., Brüggen, M. C., Alpan, O., Wang, M., Zhang, L., Torres, M. J., Shamji, M., …, & Akdis, C. A. (2026). Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases. Allergy, 81(11), 3825-3852. https://doi.org/10.1111/all.70512

Vancouver

Jiménez-Saiz R, Iborra S, Blanco C, González-Pérez R, Nuñez-Borque E, Zeyneloglu C, et al. Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases. Allergy. 2026;81(11):3825-3852. doi:10.1111/all.70512

BibTeX
@article{JimnezSaiz2026,
  author = {Jiménez-Saiz, Rodrigo and Iborra, Salvador and Blanco, Carlos and González-Pérez, Ruperto and Nuñez-Borque, Emilio and Zeyneloglu, Can and Babayev, Huseyn and Göksel, Ozlem and Göksel, Tuncay and Khaitov, Musa and Kudlay, Dmitry and Gao, Yadong and Sevim, Mustafa and Brüggen, Marie-Charlotte and Alpan, Oral and Wang, Ming and Zhang, Luo and Torres, María J and Shamji, Mohamed and Akdis, Mübeccel and Nadeau, Kari C and Ogulur, Ismail and Akdis, Cezmi A},
  title = {Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {11},
  pages = {3825--3852},
  doi = {10.1111/all.70512}
}
Start for free →